Altoida Inc. is a health technology firm that uses active digital biomarkers and cutting-edge technology in Artificial Intelligence (AI) and Augmented Reality (AR) to classify patients' risk of Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) and drive better clinical outcomes for brain diseases. Led by an international team of esteemed neuroscientists, computer scientists and medical business professionals, the company offers an FDA-cleared and CE Mark-approved medical device and brain health data platform to support early detection of Alzheimer's disease up to ten years prior to onset - with up to 94% accuracy. The company is privately held and supported by the current investor syndicate of M-Ventures (lead investor), GreySky Venture Partners, FYRFLY, VI Partners. Altoida has offices in Houston, San Diego, and Lucerne, Switzerland.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/04/20 | undisclosed |
Hikma Ventures | undisclosed | |
| 03/30/22 | $14,000,000 | Series A |
Alpana Ventures btov Partners FYRFLY Venture Partners Hikma Ventures HonorHealth M Ventures  VI Partners Whitecap Venture Partners | undisclosed |
